IP Library Granted Patent US 12709595
Granted Patent B2
US 12709595 · App. 18/346,315 · Granted Aug 18, 2026

Synthetic pathway to belzutifan

Inventors: Daniel A. DiRocco (Califon, NJ); Jackson Kenai Blender Cahn (Westfield, NJ); Wai Ling Cheung-Lee (Westfield, NJ); Stephanie W. Chun (Scotch Plains, NJ); J. Caleb Hethcox (New York, NY); Heather Claire Johnson (Jamaica Plain, MA); Jungchul Kim (Basking Ridge, NJ); Joshua N. Kolev (Califon, NJ); Birgit Kosjek (Westfield, NJ); Diane Le (Rahway, NJ); Scott D. McCann (Middlesex, NJ); John McIntosh (Brookline, MA); Jonathan P. McMullen (Scotch Plains, NJ); Jeffrey C. Moore (Westfield, NJ); William Morris (Randolph, NJ); Juan Esteban Velasquez Velez (Jersey City, NJ); Matthew S. Winston (Maplewood, NJ); Victoria Zhang (Bardonia, NY); Yong-Li Zhong (Edison, NJ)
Assignee: Merck Sharp & Dohme LLC
C07C317/14C07C315/04C12N9/0006C12P11/00C12Y101/01
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12709595
App. No.
18/346,315
Granted
Aug 18, 2026
Kind
B2
Abstract

The disclosure provides a novel process and synthetic intermediates for making belzutifan, a HIF-2α inhibitor, useful for the treatment of certain VHL-related indications and cancer.

Claims (38)

1 . A process for preparing belzutifan

comprising:

(a) contacting hydroxy indanone (5)

with a fluorinating agent under acidic conditions to yield fluoro hydroxyindanone (6),

(b) contacting the fluoro hydroxyindanone (6) with a ketoreductase comprising the full-length sequence of SEQ ID NO:2 to provide fluorodiol (7),

(c) isolating the fluorodiol (7), and

(d) converting fluorodiol (7) to belzutifan.

2 . The process of claim 1 , wherein step (b) further comprises contacting the fluoro hydroxyindanone (6) with NADP.

3 . The process of claim 1 , wherein the process further comprises preparing the hydroxy indanone (5) of step (a) by contacting indanone (4)

with FoPip4H enzyme comprising the full-length sequence of SEQ ID NO:1 and a co-substrate to provide hydroxy indanone (5).

4 . The process of claim 3 , wherein the co-substrate is α-ketoglutarate.

5 . The process of claim 3 , wherein the process further comprises preparing the indanone (4) by contacting bromo indanone (3)

with a metabisulfite salt in the presence of a Ni 2+ catalyst and a methylating agent to provide the indanone (4).

6 . The process of claim 5 , wherein the Ni 2+ catalyst is NiCl 2 -dppe.

7 . The process of claim 5 , wherein the methylating agent is selected from the group consisting of trimethyl phosphate, dimethylsulfate, methyl iodide, methyl bromide, methyl chloride, dimethyl carbonate, methyl trifluoromethane sulfonate, and trimethyloxonium tetrafluoroborate.

8 . The process of claim 5 , wherein the metabisulfite salt is an alkali metal metabisulfite salt.

9 . The process of claim 5 , wherein the process further comprises preparing the bromo indanone (3) by cyclizing phenylpropionic acid (2)

in thionyl chloride in the presence of a Lewis acid to provide the indanone (3).

10 . The process of claim 9 , wherein phenylpropionic acid (2) is prepared by reacting benzaldehyde (1)

with Meldrum's acid to provide phenylpropionic acid (2).

11 . The process of claim 1 , wherein step (d) comprises: treating fluorodiol (7) with a deoxyfluorinating agent and a base to provide trifluoro indanol (8)

and

converting trifluoro indanol (8) to belzutifan.

12 . The process of claim 11 , wherein step (d) further comprises coupling trifluoro indanol (8) with phenol (9)

to provide belzutifan.

13 . The process of claim 12 , wherein the coupling is conducted in an aqueous solution in the presence of a base.

14 . The process of claim 12 , wherein step (d) further comprises:

treating belzutifan with activated carbon;

recrystallizing decolorized belzutifan from a mixture of a dipolar aprotic solvent and water;

and isolating purified belzutifan.

15 . A process for preparing fluorodiol (7)

comprising:

(a) contacting hydroxyindanone (5)

with a fluorinating agent under acidic conditions to yield fluoro hydroxyindanone (6),

(b) contacting the fluoro hydroxyindanone (6) with a ketoreductase comprising the full-length sequence of SEQ ID NO:2 to provide fluorodiol (7); and

(c) isolating the fluorodiol (7).

16 . The process of claim 15 , wherein step (b) further comprises contacting the fluoro hydroxyindanone (6) with NADP.

17 . The process of claim 16 , wherein step (b) further comprises contacting the NADP and the fluoro hydroxyindanone (6) with a secondary alcohol.